Machine Learning

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

The latest O-RAN PlugFest showcases major AI integration and a shift to live networks, but the path to widespread commercial adoption remains complex.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

With rare dual Google accreditations, Audiencerate offers a blueprint for privacy-first advertising in a world without third-party cookies.